German drug maker Merck ups forecast for 2013

German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.

"Based on business performance in the third quarter of 2013, Merck is raising its for (operating profit) for the full year, despite negative currency effects," the company said in a statement.

Full-year earnings before interest, tax, depreciation and amortisation (EBITDA) were now projected to come out at 3.2-3.25 billion euros ($4.3-4.4 billion).

Previously, Merck had been pencilling in EBITDA of 3.1-3.2 billion euros for the whole of 2013.

"In addition to moderate organic sales growth, the main reason for this is the accelerated implementation of savings measures," Merck said.

In the three months to September, EBITDA climbed by 10.1 percent to 830.7 million euros.

Net profit rose to 340 million euros from 185 million euros a year earlier, but sales declined by 3.1 percent to 2.752 billion euros, hit by the strong euro.

spm/yad

add to favorites email to friend print save as pdf

Related Stories

German chip maker Infineon meets full-year targets

Nov 12, 2013

German semi-conductors giant Infineon said on Tuesday a strong fourth quarter had enabled it to meet its goals for the year just ended, but warned of falling sales in the current quarter.

Bayer says new products push profits higher in Q3

Oct 31, 2013

German chemicals and pharmaceuticals group Bayer, maker of Aspirin, said on Thursday that new pharmaceutical products and favourable agrochemical prices gave profits a fillip in the third quarter.

Higher prices for MS drug help drug firm Merck

May 14, 2013

(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.

Merck back to profits on lower one-time costs

Aug 06, 2013

German drug and high-tech materials company Merck KGaA bounced back from losses this time last year to record a net profit of 316 million euros ($420 million) in the second quarter.

Recommended for you

Ebola scare boosts business for US company

14 hours ago

The Ebola scare has subsided in the United States, at least temporarily, but an Alabama manufacturer is still trying to catch up with a glut of orders for gear to protect against the disease.

Thai parliament votes to ban commercial surrogacy (Update)

22 hours ago

Thailand's parliament has voted to ban commercial surrogacy after outrage erupted over the unregulated industry following a series scandals including the case of an Australian couple accused of abandoning a baby with Down's ...

Doctor behind 'free radical' aging theory dies

Nov 25, 2014

Dr. Denham Harman, a renowned scientist who developed the most widely accepted theory on aging that's now used to study cancer, Alzheimer's disease and other illnesses, has died in Nebraska at age 98.

Mexican boy who had massive tumor recovering

Nov 25, 2014

An 11-year-old Mexican boy who had pieces of a massive tumor removed and who drew international attention after U.S. officials helped him get treatment in the southwestern U.S. state of New Mexico is still recovering after ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.